Today the US Food and Drug Administration (FDA) approved secukinumab (Cosentyx) for the treatment of adults with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. This is the first anti-IL-17 biologic approved for
TOGETHER-PsA by Merola et al may be a practice-changing obesity story. Adding tirzepatide to ixekizumab improved joint outcomes at 52 weeks. Treating inflammation alone may not be enough for some patients with PsA. @rheumnow #ACR2026 #ACRBest Abstract#2942
TOGETHER-PsA at 52 weeks: ACR50 was 43.7% with ixekizumab + tirzepatide vs 15.7% with ixekizumab alone in PsA with overweight/obesity. n=271; open-label RCT. Joint, functional and metabolic outcomes improved. #2942 @Rheumnow #ACR26 #ACRBest https://t.co/zMNyrbAR5m
Merola et al, TOGETHER-PsA: At 52 weeks, ACR50 was 43.7% with ixekizumab + tirzepatide vs 15.7% with ixekizumab alone. A 28-point difference! Is addressing obesity becoming essential to optimal PsA care? @rheumnow #ACR2026 #ACRBest Abstract#2942
Today the ACR began with the Great Debate, an intriguing set of Plenary presentations, a never-ending poster hall and a plethora of stimulation oral presentation sessions. Here are a few of my favorites from today:
Bimekizumab BEATS Risankizumab in PsA 24 week results by ACR50 from H2H BE-BOLD: - wk 4 19.9% vs. 7.2% - wk 16 49.1% vs. 38% - wk 24 54.9% vs. 43.8% More fungal infx in IL17 group as expected, mild-mod Practice-changing results for PsA @RheumNow #ACRbest #ACR26 Abst2804 https://t.co/3GxVLNs1td
